Immune and inflammation-related factors alteration as a biomarker for predicting prognosis and responsiveness to PD-1 monoclonal antibody in patients with recurrent cervical cancer

Purpose: We aimed to elucidate the potential mechanisms of effective responsiveness to PD-1 monoclonal antibody and evaluate more reliable biomarkers for improving the predictive utility of the dominant populations of recurrent cervical cancer (RCC) to receive immunotherapy. Methods: Peripheral blood samples of PD-L1 positive patients with RCC treated with second-line PD-1 monoclonal antibody were collected prior to treatment initiation and after the treatment. Differentially expressed genes (DEGs) were analyzed between partial response (PR) patient and progressive disease (PD) patients. Peripheral blood samples of PD-L1 positive patients with RCC treated with second-line PD-1 monoclonal antibody were collected prior to treatment initiation and after the treatment. Differentially expressed genes (DEGs) were analyzed between partial response (PR) patient and progressive disease (PD) patients.